Dutch Startup HeartEye Raises €1.67 Million to Revolutionize Heart Diagnostics Outside Hospitals
Netherlands, Friday, 10 April 2026.
HeartEye’s groundbreaking wireless ECG recorder enables hospital-grade cardiac diagnostics in under one minute anywhere outside traditional clinical settings. The Dutch medtech company secured funding from ROM InWest and notable tech veterans to accelerate market introduction of their patented 12-channel device. This innovation addresses the massive global shift toward preventive cardiac care, with the heart irregularity detection market projected to grow 7.2% annually through 2035, driven by aging populations and rising cardiovascular disease rates worldwide.
Revolutionary Healthtech Innovation Transforms Cardiac Care Access
HeartEye represents a significant advancement in healthtech innovation, specifically targeting the critical gap in accessible cardiac diagnostics [1]. The Dutch medtech startup has developed a patented mobile 12-channel ECG recorder that delivers hospital-grade cardiac diagnostic capabilities outside traditional clinical environments [1]. This wireless device transforms what was previously a time-consuming and complex process requiring trained professionals into a simple procedure that takes less than one minute to complete [1]. The innovation addresses a fundamental challenge in preventive cardiac care by enabling early detection of potential heart conditions in settings ranging from general practitioner offices to nursing homes, and eventually in patients’ own homes [1].
Strategic Funding Round Drives Market Introduction
The €1.675 million funding round completed in April 2026 was strategically led by ROM InWest, with participation from prominent technology veterans including Schuberg Philis co-founder Pim Berger and Mphasis co-founder Jeroen Tas [1]. Health Innovations, making its second investment in the company, also participated in this funding round [1]. ROM InWest positioned itself to guide HeartEye through the critical development phase, recognizing that venture capital partners typically enter either during prototype development or after CE certification and market introduction, when technological and market-related risks have been substantially reduced [1]. This capital injection will enable HeartEye to execute pivotal clinical studies and advance development of their AI software, while simultaneously building production capacity to meet anticipated demand following market approval [1].
Technology Mechanics and Clinical Application
HeartEye’s fully wireless ECG recorder operates as a handheld, user-friendly device that enables general practitioners, assistants, or nurses to create 12-channel ECGs in under one minute [1]. The technology integrates with a digital platform that allows cardiac recordings to be shared with physicians or specialists for interpretation and diagnostic support [1]. This approach facilitates professional, high-quality cardiac diagnostics outside hospital environments, enabling earlier detection of heart problems to ensure appropriate patients reach cardiologists promptly while preventing unnecessary hospital referrals [1]. The system aims to reduce mortality from cardiac issues while simultaneously cutting healthcare costs through more efficient care delivery and reduced workload pressures [1].
Market Context and Growth Trajectory
HeartEye’s innovation aligns with broader market trends in the global heart beat irregularity detection device sector, which is experiencing structural transformation from 2026 to 2035 [2]. The market is shifting from hospital-centric monitoring toward decentralized, ambulatory, and home-based applications enabled by wearable technologies [2]. Growth drivers include rising cardiovascular disease prevalence, aging global populations, and technological advancements in wearable devices [2]. Home healthcare and remote patient monitoring represents the fastest-growing segment with an estimated 28% market share, while hospitals and clinics account for approximately 38% of current market share as they transition to central hubs for interpreting externally generated data [2]. IndexBox projects the global heart beat irregularity detection device market will grow at a 7.2% compound annual growth rate from 2026 to 2035, with the market index reaching approximately 195 by 2035 compared to a 2025 baseline of 100 [2].